Perioperative blood transfusions do not impact overall and disease-free survival after curative rectal cancer resection: A propensity score analysis

Annals of Surgery

Volumn 259, Issue 1, 2014, Pages 131-138

  Warschkow, Rene ^a,b   Güller, Ulrich ^a,c   Köberle, Dieter ^a   Müller, Sascha A ^a   Steffen, Thomas ^a   Thurnheer, Martin ^a   Schmied, Bruno M ^a   Tarantino, Ignazio ^a  

^a Kantonsspital St Gallen ^*  (Switzerland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Adverse effects; Blood transfusion; Postoperative; Rectal cancer; Survival

Indexed keywords

FLUOROURACIL;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OPERATIVE BLOOD LOSS; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROPENSITY SCORE; RECTUM CANCER; RECTUM RESECTION; RETROSPECTIVE STUDY;

AGED; BLOOD TRANSFUSION; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIOPERATIVE PERIOD; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84891632336     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318287ab4d     Document Type: Article

References (54)

1. Klein HG. Immunomodulatory aspects of transfusion: A once and future risk? Anesthesiology. 1999;91:861-865.
2. Burrows L, Tartter P. Effect of blood transfusions on colonic malignancy recurrent rate. Lancet. 1982;2:662.
3. Nielsen HJ. Detrimental effects of perioperative blood transfusion. Br J Surg. 1995;82:582-587.
4. Vamvakas EC. Perioperative blood transfusion and cancer recurrence: Metaanalysis for explanation. Transfusion. 1995;35:760-768.
5. Wolters U, Stutzer H, Keller HW, et al. Colorectal cancer-A multivariate analysis of prognostic factors. Eur J Surg Oncol. 1996;22:592-597.
6. Sabalic S, Kovacevic D, Glavic Z, et al. The immunomodulation effect of allogenic blood transfusion in colorectal cancer-A new approach. Coll Antropol. 2006;30:885-893.
7. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006:CD005033.
8. Hill GE, Frawley WH, Griffith KE, et al. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: A meta-Analysis. J Trauma. 2003;54:908-914.
9. Warschkow R, Steffen T, Thierbach J, et al. Risk factors for anastomotic leakage after rectal cancer resection and reconstruction with colorectostomy. A retrospective study with bootstrap analysis. Ann Surg Oncol. 2011;18:2772-2782.
10. Koch M, Antolovic D, Reissfelder C, et al. Leucocyte-depleted blood transfusion is an independent predictor of surgical morbidity in patients undergoing elective colon cancer surgery-A single-center analysis of 531 patients. Ann Surg Oncol. 2011;18:1404-1411.
11. Blumberg N, Heal JM. Immunomodulation by blood transfusion: An evolving scientific and clinical challenge. Am J Med. 1996;101:299-308.
12. Blajchman MA. Immunomodulation and blood transfusion. Am J Ther. 2002;9:389-395.
13. Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusionassociated immunomodulation: Fact or fiction? Blood. 2001;97:1180-1195.
14. Barr PJ, DonnellyM,Morris K, et al. The epidemiology of red cell transfusion. Vox Sang. 2010;99:239-250.
15. Pham JC, Catlett CL, Berenholtz SM, et al. Change in use of allogeneic red blood cell transfusions among surgical patients. J AmColl Surg. 2008;207:352-359.
16. Ota D, Alvarez L, Lichtiger B, et al. Perioperative blood transfusion in patients with colon carcinoma. Transfusion. 1985;25:392-394.
17. Bentzen SM, Balslev I, Pedersen M, et al. Blood transfusion and prognosis in Dukes' B and C colorectal cancer. Eur J Cancer. 1990;26:457-463.
18. Tang RP, Wang JY, Chien CRC, et al. The association between perioperative blood-Transfusion and survival of patients with colorectal cancer. Cancer. 1993;72:341-348.
19. Garau I, Benito E, Bosch FX, et al. Blood-Transfusion has no effect on colorectal-cancer survival-A population-based study. Eur J Cancer. 1994;30A:759-764.
20. Steup WH, Hojo K, Moriya Y, et al. An analysis on the effect of bloodtransfusion on recurrence and survival in patients undergoing extended lymphadenectomy for colorectal cancer. Hepatogastroenterology. 1994;41:253-259.
21. McAlister FA, Clark HD,Wells PS, et al. Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: A meta-Analysis of unconfounded studies. Br J Surg. 1998;85:171-178.
22. Jagoditsch M, Pozgainer P, Klingler A, et al. Impact of blood transfusions on recurrence and survival after rectal cancer surgery. Dis Colon Rectum. 2006;49:1116-1130.
23. Lobaziewicz W, Kolodziejski L. The impact of homologous packed red blood cell transfusion on patients' survival after radical surgical treatment of colorectal cancer. Acta Chirurgica Belgica. 2008;108:524-531.
24. Zdravkovic D, Bilanovic D, Randjelovic T, et al. Allogeneic blood transfusion in patients in Dukes B stage of colorectal cancer. Med Oncol. 2011;28:170-174.
25. Tarantino I, Warschkow R, Worni M, et al. Elevated preoperative CEA is associated with worse survival in stage I-III rectal cancer patients. Br J Cancer. 2012;107:266-274.
26. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-526.
27. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757-763.
28. Joffe MM, Rosenbaum PR. Invited commentary: Propensity scores. Am J Epidemiol. 1999;150:327-333.
29. Rosenbaum PR. Model-based direct adjustment. J Am Stat Assoc. 1987;82:387-394.
30. Rosenbaum PR. Optimal matching for observational studies. J Am Stat Assoc. 1989;84:1024-1032.
31. Hansen BB, Klopfer SO.Optimal full matching and related designs via network flows. J Comput Graph Statist. 2006;15:609-627.
32. Ho DE, Imai K, King G, et al. MatchIt: Nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42:1-28.
33. Therneau TM, Grambsch PM, Pankratz VS. Penalized survival models and frailty. J Comput Graph Statist. 2003;12:156-175.
34. Govindarajulu US, Lin H, Lunetta KL, et al. Frailty models: Applications to biomedical and genetic studies. Stat Med. 2011;30:2754-2764.
35. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med. 1982;1:121-129.
36. Amato AC, Pescatori M. Effect of perioperative blood transfusions on recurrence of colorectal cancer: Meta-Analysis stratified on risk factors. Dis Colon Rectum. 1998;41:570-585.
37. Gonzalez ZM, Barrase AG, Renau AR. Anaemia, iron, transfusion and therapeutic alternatives. A review from a surgical perspective. Cir Esp. 2010;88:358-368.
38. Duran L, Moral V, Basora M, et al. Epidemiological study of preoperative anaemia in surgical oncology patients in Spain. RECIRON Study. Cir Esp. 2009;85:45-52.
39. Weber RS, Jabbour N, Martin RCG. Anemia and transfusions in patients undergoing surgery for cancer. Ann Surg Oncol. 2008;15:34-45.
40. Leichtle SW, Mouawad NJ, Lampman R, et al. Does preoperative anemia adversely affect colon and rectal surgery outcomes? J Am Coll Surg. 2011;212:187-194.
41. Bower MR, Ellis SF, Scoggins CR, et al. Phase II comparison study of intraoperative autotransfusion for major oncologic procedures. Ann Surg Oncol. 2011;18:166-173.
42. Busch OR, Hop WC, Hoynck van Papendrecht MA, et al. Blood transfusions and prognosis in colorectal cancer. N Engl J Med. 1993;328:1372-1376.
43. Busch OR, Hop WC, Marquet RL, et al. Blood transfusions and local tumor recurrence in colorectal cancer. Evidence of a noncausal relationship. Ann Surg. 1994;220:791-797.
44. Busch OR, Hop WC, Marquet RL, et al. The effect of blood transfusions on survival after surgery for colorectal cancer. Eur J Cancer. 1995;31A:1226-1228.
45. Mortensen FV, Jensen LS, Sorensen HT, et al. Cause-specific mortality associated with leukoreduced, buffy coat-depleted, or no blood transfusion after elective surgery for colorectal cancer: A posttrial 15-year follow-up study. Transfusion. 2011;51:259-263.
46. Stramer SL. Current risks of transfusion-Transmitted agents: A review. Arch Pathol Lab Med. 2007;131:702-707.
47. Heiss MM, Mempel W, Delanoff C, et al. Blood transfusion-modulated tumor recurrence-first results of a randomized study of autologous versus allogeneic blood-Transfusion in colorectal cancer surgery. J Clin Oncol. 1994;12:1859-1867.
48. Houbiers JGA, Brand A, Vandewatering LMG, et al. Randomized controlled trial comparing transfusion of leukocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet. 1994;344:573-578.
49. Marquet RL, Busch OR, Jeekel J, et al. Are allogeneic blood transfusions acceptable in elective surgery in colorectal carcinomä. Eur J Cancer. 1999;35:352-360.
50. Houbiers JGA, Vandewatering LMG, Verwey PJM, et al. Leukocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer-reply. Lancet. 1994;344:1430-1431.
51. Jung SH, Chow SC, Chi EM. A note on sample size calculation based on propensity analysis in nonrandomized trials. J Biopharm Stat. 2007;17: 35-41.
52. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26: 303-312.
53. Quirke P, Steele R, Monson J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: A prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet. 2009;373:821-828.
54. Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688-8696.